PARP Inhibitors in Advanced Ovarian Cancer

Blum Center Program: Advanced Ovarian Cancer - Diagnosis, Treatment & Future DirectionsПодробнее

The Role of PARP Inhibitors in Advanced Prostate CancerПодробнее

Precision Medicine in Oncology: Ep.9 DEBATE - Is PARP inhibitor maintenance therapy in first-line...Подробнее

Integrating New Research Information into Current Clinical Care — Ovarian CancerПодробнее

Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ov...Подробнее

PARP Inhibitors in Advanced Prostate Cancer CareПодробнее

Tuvusertib and niraparib in advanced unresectable solid tumorsПодробнее

Evolution of the Care of Patients With Advanced Ovarian CancerПодробнее

Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ov...Подробнее

Ovarian Cancer | Breakfast with the Investigators: Ovarian CancerПодробнее

PARP Inhibitors: Putting the Brakes on Ovarian CancerПодробнее

Advanced Ovarian Cancer: 20% Disease-Free Survival at 10 YearsПодробнее

PARP Inhibitors & Advanced Prostate CancerПодробнее

The Role of PARP Inhibitors in Advanced Prostate Cancer (2023)Подробнее

#olaparib | Uses, Dosage, Side Effects & Mechanism | LynparzaПодробнее

Episode 3: HRD What? HRD Why?Подробнее

PARP Inhibitors in Advanced Prostate Cancer CareПодробнее

A Webinar on PARP Inhibitors in Epithelial Ovarian CancerПодробнее

Upgrading the Treatment Algorithm for Advanced Ovarian CancerПодробнее

LYNPARZA (olaparib)- advanced epithelial ovarian, fallopian tube or primary peritoneal cancerПодробнее